Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Balstilimab + Botensilimab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Balstilimab | AGEN-2034|AGEN2034 | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 122 | Balstilimab (AGEN2034) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 ligand (CD274), potentially resulting in enhanced anti-tumor immune response (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 3086-3086). | |
Botensilimab | AGEN1181|AGEN 1181|AGEN-1181 | CTLA4 Antibody 31 Immune Checkpoint Inhibitor 149 | Botensilimab (AGEN1181) is an antibody that targets CTLA4, potentially resulting in increased anti-tumor immune response (Journal for ImmunoTherapy of Cancer 2021;9). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06300463 | Phase II | Balstilimab + Botensilimab + GS-1423 Balstilimab + Botensilimab | Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases | Recruiting | USA | 0 |
NCT05571293 | Phase II | Balstilimab + Botensilimab | Combination Immunotherapy in Colorectal Cancer (NEST-1) | Recruiting | USA | 0 |
NCT05928806 | Phase II | Balstilimab + Botensilimab Ipilimumab + Nivolumab | Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial (ARCITECT) | Recruiting | USA | 0 |
NCT06279130 | Phase II | Balstilimab Balstilimab + Botensilimab | Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations (NEOASIS) | Recruiting | NLD | 0 |
NCT05608044 | Phase II | Balstilimab + Botensilimab Botensilimab | A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer | Active, not recruiting | USA | ITA | FRA | ESP | BRA | BEL | 2 |
NCT06268015 | Phase II | Balstilimab + Botensilimab + Fluorouracil + Leucovorin + Oxaliplatin + Panitumumab Balstilimab + Botensilimab Balstilimab + Bevacizumab + Botensilimab + Fluorouracil + Leucovorin + Oxaliplatin | Botensilimab and Balstilimab Optimization in Colorectal Cancer (BBOpCo) | Recruiting | USA | 0 |
NCT06346197 | Phase III | Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin Capecitabine + Nivolumab + Oxaliplatin Balstilimab + Botensilimab | Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas (CIME) | Not yet recruiting | FRA | 0 |
NCT06095674 | Phase I | Balstilimab + Botensilimab | ImmunoTHerapy Adjacent to Cervical CAncer (ITHACA) Study (ITHACA) | Not yet recruiting | NLD | 0 |
NCT06575725 | Phase II | Balstilimab + Botensilimab + Regorafenib Balstilimab + Botensilimab | Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Metastatic Microsatellite Stable Colorectal Cancer | Withdrawn | 0 |